Takeda, Abingworth provide a $100M bankroll for an upstart T cell player, building in a buyout option
Over the past year Takeda has been ripping up its old global R&D organization and creating a new one, with a whole new set of collaborators. Today it’s taking a front row seat at a London-based startup, pitching in on a $100 million package to bankroll the construction of GammaDelta Therapeutics’ T cell platform while taking an option to acquire the biotech.
Things are moving fast at GammaDelta, which has some marquee Golden Triangle names behind it. Takeda and its venture backer Abingworth are putting in the cash, with Takeda getting an equity stake along with its buyout option.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.